Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Thomas F. Patterson(National Institute of Allergy and Infectious Diseases), John R. Graybill(Office of Infectious Diseases), B. Dupont(Délégation Paris 5), William R. Kirkpatrick(The University of Texas at San Antonio Health Science Center), Michael G. Rinaldi(Murphy Oil Corporation (United States)), John W. Hiemenz(University of Florida), John R. Wingard(University of Florida Health), Mary H. White, David A. Stevens(Stanford University)
Cited by 793
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|2.8k
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
|Clinical Infectious Diseases|2019|2.8k
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
|Clinical Infectious Diseases|2008|2.7k